For instance, radiomic features that detect HER2 enrichment, a predictor of improved response to HER2-targeted therapy [58], might strongly predict pCR in HER2+ tumors, but they would likely have little predictive value for TN breast cancer. Here, ERBB2 is linked to breast cancer.